Malaysia
· Delayed Price · Currency is MYR Pharmaniaga Berhad Statistics
Total Valuation
KLSE:PHARMA has a market cap or net worth of MYR 252.22 million. The enterprise value is 1.29 billion.
| Market Cap | 252.22M |
| Enterprise Value | 1.29B |
Important Dates
The next estimated earnings date is Wednesday, August 20, 2025.
| Earnings Date | Aug 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
KLSE:PHARMA has 1.44 billion shares outstanding. The number of shares has increased by 2.92% in one year.
| Current Share Class | 1.44B |
| Shares Outstanding | 1.44B |
| Shares Change (YoY) | +2.92% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 5.05% |
| Owned by Institutions (%) | 40.71% |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 1.86 and the forward PE ratio is 5.00.
| PE Ratio | 1.86 |
| Forward PE | 5.00 |
| PS Ratio | 0.07 |
| PB Ratio | -2.12 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 2.73 |
| P/OCF Ratio | 2.10 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.26, with an EV/FCF ratio of 13.98.
| EV / Earnings | 9.53 |
| EV / Sales | 0.34 |
| EV / EBITDA | 4.26 |
| EV / EBIT | 4.86 |
| EV / FCF | 13.98 |
Financial Position
The company has a current ratio of 0.65
| Current Ratio | 0.65 |
| Quick Ratio | 0.37 |
| Debt / Equity | n/a |
| Debt / EBITDA | 3.80 |
| Debt / FCF | 12.48 |
| Interest Coverage | 3.70 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 7.91% |
| Return on Invested Capital (ROIC) | 16.59% |
| Return on Capital Employed (ROCE) | 764.18% |
| Revenue Per Employee | 1.10M |
| Profits Per Employee | 38,765 |
| Employee Count | 3,502 |
| Asset Turnover | 1.83 |
| Inventory Turnover | 5.83 |
Taxes
In the past 12 months, KLSE:PHARMA has paid 62.78 million in taxes.
| Income Tax | 62.78M |
| Effective Tax Rate | 31.29% |
Stock Price Statistics
The stock price has decreased by -54.88% in the last 52 weeks. The beta is 0.77, so KLSE:PHARMA's price volatility has been lower than the market average.
| Beta (5Y) | 0.77 |
| 52-Week Price Change | -54.88% |
| 50-Day Moving Average | 0.20 |
| 200-Day Moving Average | 0.28 |
| Relative Strength Index (RSI) | 49.00 |
| Average Volume (20 Days) | 45,843,950 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KLSE:PHARMA had revenue of MYR 3.85 billion and earned 135.76 million in profits. Earnings per share was 0.09.
| Revenue | 3.85B |
| Gross Profit | 543.79M |
| Operating Income | 265.92M |
| Pretax Income | 200.64M |
| Net Income | 135.76M |
| EBITDA | 292.94M |
| EBIT | 265.92M |
| Earnings Per Share (EPS) | 0.09 |
Balance Sheet
The company has 138.19 million in cash and 1.15 billion in debt, giving a net cash position of -1.02 billion or -0.70 per share.
| Cash & Cash Equivalents | 138.19M |
| Total Debt | 1.15B |
| Net Cash | -1.02B |
| Net Cash Per Share | -0.70 |
| Equity (Book Value) | -119.09M |
| Book Value Per Share | -0.10 |
| Working Capital | -746.65M |
Cash Flow
In the last 12 months, operating cash flow was 120.26 million and capital expenditures -27.75 million, giving a free cash flow of 92.51 million.
| Operating Cash Flow | 120.26M |
| Capital Expenditures | -27.75M |
| Free Cash Flow | 92.51M |
| FCF Per Share | 0.06 |
Margins
Gross margin is 14.13%, with operating and profit margins of 6.91% and 3.53%.
| Gross Margin | 14.13% |
| Operating Margin | 6.91% |
| Pretax Margin | 5.21% |
| Profit Margin | 3.53% |
| EBITDA Margin | 7.61% |
| EBIT Margin | 6.91% |
| FCF Margin | 2.40% |
Dividends & Yields
KLSE:PHARMA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.92% |
| Shareholder Yield | n/a |
| Earnings Yield | 53.83% |
| FCF Yield | 36.68% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 5, 2021. It was a forward split with a ratio of 5.
| Last Split Date | Jul 5, 2021 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
KLSE:PHARMA has an Altman Z-Score of 1.64 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.64 |
| Piotroski F-Score | 7 |